Oral Health Group
News

A treatment for osteoporosis and bone cancer, employed for the first time in dental filling procedures


November 3, 2014
by Oral Health

Salvatore Sauro, Professor of Biomaterials and Minimally Invasive Dentistry at University CEU Cardenal Herrera (CEU-UCH) in Valencia (Spain), has been working on an impressive research program where the main objective is the development of bioactive restorative and/or preventive materials with potential regenerative properties for dental tissues.

Salvatore Sauro, directed a paper that was published in the Journal of Dental in collaboration with international researchers from Finland, Brazil, United States and United Kingdom. The research report has demonstrated how the use of zoledronic acid which is employed as a treatment for osteoporosis and bone cancer , in combination with bioactive ion-releasing resin-based restorative materials used as dental adhesive, reduces the degradation of dentin collagen and promotes remineralisation at the resin-dentine interface.

Zoledronic acid is a class of medications called bisphosphonates. It works by slowing bone breakdown, increasing bone density and decreasing the amount of calcium released from the bones into the blood, so it’s used in many ways as treating Pajet’s Disease, also used to prevent or treat osteoporosis in women who have undergone menopause, and applied in cancer chemotherapy to treat bone damage caused by multiple or by cancer that began in another part of the body but has spread to the bones. But For the first time Zoledronic acid has been tested in combination with bioactive resin-based adhesive systems and applied in restorative dentistry.
 
To keep reading, please visit: http://asnanportal.com/index.php/reports/news/744-a-treatment-for-osteoporosis-and-bone-cancer,-employed-for-the-first-time-in-dental-filling-procedures.